The impressive 2007 sales growth of cancer drug Nexavar, which increased 125 percent over the year before, was overshadowed by the early termination of an ongoing Phase III study of the drug in non-small-cell lung cancer (NSCLC) due to lack of efficacy, news that sent shares of Onyx Pharmaceuticals Inc. falling 26.4 percent. (BioWorld Today)